{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:09:10Z","timestamp":1774994950739,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12185-017-2378-y","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T04:39:15Z","timestamp":1511843955000},"page":"712-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia"],"prefix":"10.1007","volume":"107","author":[{"given":"Shin-ichiro","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Shirato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iekuni","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"2378_CR2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"2378_CR3","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"2378_CR4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","volume":"18","author":"D Kitagawa","year":"2013","unstructured":"Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18:110\u201322.","journal-title":"Genes Cells"},{"key":"2378_CR5","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","volume":"17","author":"PC Amrein","year":"2011","unstructured":"Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:2977\u201386.","journal-title":"Clin Cancer Res"},{"key":"2378_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2013.10.004","volume":"38","author":"AP Kater","year":"2014","unstructured":"Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, et al. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leuk Res. 2014;38:34\u201341.","journal-title":"Leuk Res"},{"key":"2378_CR7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-010-1530-7","volume":"68","author":"J Hebb","year":"2011","unstructured":"Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, et al. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol. 2011;68:643\u201351.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2378_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10428190802563363","volume":"50","author":"TM Wildes","year":"2009","unstructured":"Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma. 2009;50:137\u201340.","journal-title":"Leuk Lymphoma"},{"key":"2378_CR9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","volume":"129","author":"K Krysiak","year":"2017","unstructured":"Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129:473\u201383.","journal-title":"Blood"},{"key":"2378_CR10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"},{"key":"2378_CR11","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","volume":"128","author":"CS Ujjani","year":"2016","unstructured":"Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016;128:2510\u20136.","journal-title":"Blood"},{"key":"2378_CR12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H Lavallade de","year":"2013","unstructured":"de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227\u201338.","journal-title":"Blood"},{"key":"2378_CR13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23:477\u201385.","journal-title":"Leukemia"},{"key":"2378_CR14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578\u201385.","journal-title":"Blood"},{"key":"2378_CR15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49:615\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2378_CR16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"2378_CR17","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166\u201376.","journal-title":"Blood"},{"key":"2378_CR18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","volume":"30","author":"MB Miranda","year":"2016","unstructured":"Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30:1255\u201362.","journal-title":"Leukemia"},{"key":"2378_CR19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ajh.2830310215","volume":"31","author":"WR Drobyski","year":"1989","unstructured":"Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin\u2019s lymphoma: clinical and pathogenetic considerations. Am J Hematol. 1989;31:138\u201341.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2378-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T17:56:07Z","timestamp":1526493367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2378-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2378-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,28]]}}}